Exogenous reproductive hormone use in breast cancer survivors and previvors

Exogenous reproductive hormone use in breast cancer survivors and previvorsExogenous reproductive hormone use in breast cancer survivors and previvors, Published online: 23 January 2018; doi:10.1038/nrclinonc.2017.207The safety of elective exogenous hormonal exposure among breast cancer survivors or women at high risk of having the disease has been debated for decades. Herein, the authors discuss the available data and present clinical recommendations regarding four areas of potential exogenous exposure to hormones: hormonal contraception; systemic hormone-replacement therapy; localized hormone-replacement therapy; and hormonal manipulation for fertility preservation or enhancement. Further research is needed to improve patient management in the future.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research